ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

RNAC vs INO // FORWARD P/E MULTIPLE

Cartesian Therapeutics Inc. (NASDAQ) VS. Inovio Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: RNAC 0 — INO 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RNAC VS. INO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC RNAC INO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) -65.00% -65.00% 0.00 TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 2/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 40.2 72.7 -32.50 INO /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple ACTIVE — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $191.8M $195.4M -$3.6M INO /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR RNAC REV INO REV RNAC GROSS % INO GROSS % RNAC FCF INO FCF
FY 2025 $400.0K $65.3K — — -$79.4M -$88.9M
FY 2024 $38.3M $217.8K — — -$32.8M -$104.6M
FY 2023 $26.0M $832.0K — — -$51.2M -$124.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RNAC // BETA —
INO // BETA —